Abstract:Achieving diverse representation in oncology studies is an ongoing challenge., Responding to calls to advance health equity in clinical trials, Congress amended the Food Drug and Cosmetic Act to require trial sponsors to submit a "diversity action plan" to the FDA with a study's protocol. This requirement to plan for diverse trial recruitment drives a need to innovate approaches for site selection and trial recruitment that go beyond mirroring race-ethnicity distributions from the US Census or disease prevalence. We present a novel framework that nests clinical trials in a longitudinal patient registry to achieve diverse representation across multiple domains, evaluate site-selection and recruitment strategies, and examine health equity across the cancer patient journey. Implementing a registry to support longitudinal data collection (i.e., a cohort study), we establish a continuous view of participant characteristics including demographic and social determinants of health, treatment received, and relevant outcomes. Nesting clinical trials within the structure of the cohort, we can select sites and recruit for diverse representation to achieve equity goals. This framework involves a multi-layer analysis of external population statistics and internal reference registry to gauge the pool of eligible participants and calibrate the sampling strategy and recruitment expectations to the realities of clinical representation. Moreover, where clinical representation differs from population statistics, the registry offers an opportunity to report benchmarks for diversity and compare to site-level and study-level realized enrollment and feasibility. In conclusion, the path to health equity in oncology trials depends on a capacity to ask and answer the right questions in planning. What specific aspects of diversity are we aiming to capture? How do these aspects impact outcomes? We advocate for a dynamic planning process that continuously reevaluates goals and strategies in the face of enrollment data and evolving population demographics. By utilizing a registry with longitudinal follow-up, we can set forth clear expectations, transparently report on the progress of inclusion efforts, and candidly address feasibility challenges. We present a structured framework for trial sponsors to not only comply with the forthcoming requirement for diversity action plans, but ultimately to advance the goal of equitable cancer care through research that truly reflects the complex intersectional diversity of those impacted by the disease. Citation Format: Halcyon G. Skinner, Caroline Marra, April I. Alexandrow, Hamsa L. Subramaniam, Nathan C. Nussbaum, Joseph B. Franklin, Edgar P. Simard, Amy P. Abernethy. Planning for health equity in oncology trials: Expectations and feasibility [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1311.

A Vision for Democratizing Next-Generation Oncology Clinical Trials

Advancing Global Health Equity in Oncology Clinical Trial Access

Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers

A call to action to advance patient‐focused and decentralized clinical trials

Abstract 1311: Planning for health equity in oncology trials: Expectations and feasibility

Global adoption of remote technologies to enable patient-centric oncology clinical trials: Analysis by the Bloomberg New Economy International Cancer Coalition.

Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition

Next-Generation Clinical Trials and Research with Successful Collaborations

Clinical Trial Access in Diverse Populations

Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement

Remote Monitoring and Data Collection for Decentralized Clinical Trials

Advancing Access and Equity: the Vision of a New Generation in Cancer Control.

A comprehensive analysis of patient demographics and disparities in contemporary oncology clinical trials (2022-2023).

Modernize Precision Oncology With Decentralized Trial Tools

Advancing Digital Health Innovation in Oncology: Priorities for High-Value Digital Transformation in Cancer Care

Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort

Turning the Tide Against Cancer Through Sustained Medical Innovation: The Pathway to Progress

Digital clinical trials: creating a vision for the future

The Next Horizon of Drug Development: External Control Arms and Innovative Tools to Enrich Clinical Trial Data

Next generation clinical trials: Seamless designs and master protocols

How patient-clinician education can strengthen partnerships and promote tangible actions to improve clinical trial diversity in breast and lung cancer trials.